Piper Jaffray Reiterates Overweight on Mallinckrodt (MNK) Following Solid 1Q Results

Go back to Piper Jaffray Reiterates Overweight on Mallinckrodt (MNK) Following Solid 1Q Results

Mallinckrodt plc Reports Fiscal 2016 First Quarter Results

February 2, 2016 6:01 AM EST

CHESTERFIELD, United Kingdom, Feb. 2, 2016 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today reported results for the first quarter of fiscal 2016. Amounts reported reflect presentation of the company's former contrast media and delivery systems (CMDS) business as a discontinued operation. Unless otherwise noted, all comparisons of first quarter fiscal 2016 performance are to the first quarter of fiscal... More

Mallinckrodt Completes Acquisition Of Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company

February 1, 2016 8:50 AM EST

CHESTERFIELD, United Kingdom, Feb. 1, 2016 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, today announced it closed the acquisition of the global portfolio of three commercial-stage topical hemostasis drugs from The Medicines Company. The portfolio includes RECOTHROM® Thrombin topical (Recombinant), PreveLeak Surgical Sealant, and RAPLIXA (Fibrin Sealant (Human)).

Under Mallinckrodt's acquire to invest operating model, the company will invest in market development of RECOTHROM, PreveLeak and RAPLIXA, all... More